Last update April 23, 2025

Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol

Compatible

Safe product and/or breastfeeding is the best option.

Natural product from and isomer of glucose, found in cereals, fruits, nuts and legumes, as well as animal viscera and milk. It is metabolised to glucose. Considered as part of vitamin B (Bh) with no clear evidence of vitamin B activity or deficiency. It is being used in polycystic ovary syndrome, PCOS. (Lete 2024, Greff 2023)

At the date of the last update we found no published data on its excretion in breast milk.

It is found naturally in breast milk, in higher concentrations than in cow's milk, goat's milk and commercial infant formulas. (Bakshi 2023, Huisman 1996, Pereira 1990, Jenness 1979)

There are higher concentrations in newborn plasma than in the plasma of their mothers (Pereira 1990). Breastfed infants increase their plasma inositol levels more than those fed with formula or parenteral nutrition. (Pereira 1990)

Inositol contributes to neural development and interconnection and, together with folic acid, prevents neural tube defects during pregnancy. (Chade 2024, Bakshi 2023, Paquette 2023)

It is used in the neonatal period to treat lung problems and retinopathy associated with prematurity (Bakshi 2023, Fang 2016, Brown 2009, Hallman 1992), although there is no consensus on its effectiveness and possible side effects. (Howlett 2019, DU 2019, Phelps 2016)

There are no clear therapeutic indications and no known cases of poisoning due to overdose of this product. A maximum daily amount of inositol (hexaphosphate) of 2,000 mg is acceptable from a safety point of view for use as a food supplement. (AESAN 2012)

Alternatives

We do not have alternatives for Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol is also known as Inositol.


Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol in other languages or writings:

Groups

Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol in its composition:

  • Dertrase™. Contains other elements than Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol in its composition
  • Fersitol™. Contains other elements than Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol in its composition
  • Inositech
  • Ovusitol™. Contains other elements than Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol in its composition
  • Ovusitol D™. Contains other elements than Myoinositol; Mesoinositol; Cyclohexitol; Cyclohexanhexol in its composition

Pharmacokinetics

Variable Value Unit
Molecular weight 180 daltons

References

  1. Chade ES, Júnior OR, Souza NMP, da Silva AJOK, Ferreira LM, Reolon JB, Bonini JS, Rego FGM, Sari MHM. The Influence of Nutritional Status on Brain Development: Benefits of Exclusive Breastfeeding. Pediatr Rep. 2024 Aug 24;16(3):724-735. Abstract Full text (link to original source)
  2. Lete I, Martínez A, Lasaga I, Centurión E, Vesga A. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecol Endocrinol. 2024 Dec;40(1):2301554. Abstract Full text (link to original source)
  3. Bakshi S, Paswan VK, Yadav SP, Bhinchhar BK, Kharkwal S, Rose H, Kanetkar P, Kumar V, Al-Zamani ZAS, Bunkar DS. A comprehensive review on infant formula: nutritional and functional constituents, recent trends in processing and its impact on infants' gut microbiota. Front Nutr. 2023 Jun 21;10:1194679. Abstract Full text (link to original source)
  4. Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, Park S, Hegyi P, Nyirády P, Ács N, Várbíró S, Horváth EM. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023 Jan 26;21(1):10. Abstract Full text (link to original source)
  5. Paquette AF, Carbone BE, Vogel S, Israel E, Maria SD, Patil NP, Sah S, Chowdhury D, Kondratiuk I, Labhart B, Morrow AL, Phillips SC, Kuang C, Hondmann D, Pandey N, Biederer T. The human milk component myo-inositol promotes neuronal connectivity. Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2221413120. Abstract Full text (link to original source)
  6. Howlett A, Ohlsson A, Plakkal N. Inositol in preterm infants at risk for or having respiratory distress syndrome. Cochrane Database Syst Rev. 2019 Jul 8;7(7):CD000366. Abstract Full text (link to original source)
  7. Du Y, He Y, Wang YL, Zhou JG, Chen C. The efficacy and safety of inositol supplementation in preterm infants to prevent retinopathy of prematurity: a systematic review and meta-analysis. BMC Ophthalmol. 2019 Jun 25;19(1):135. Abstract Full text (link to original source)
  8. Fang JL, Sorita A, Carey WA, Colby CE, Murad MH, Alahdab F. Interventions To Prevent Retinopathy of Prematurity: A Meta-analysis. Pediatrics. 2016 Abstract
  9. Phelps DL, Ward RM, Williams RL, Nolen TL, Watterberg KL, Oh W, Goedecke M, Ehrenkranz RA, Fennell T, Poindexter BB, Cotten CM, Hallman M, Frantz ID 3rd, Faix RG, Zaterka-Baxter KM, Das A, Ball MB, Lacy CB, Walsh MC, Carlo WA, Sánchez PJ, Bell EF, et al. Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res. 2016 Aug;80(2):209-17. Abstract Full text (link to original source)
  10. AESAN. Informe del Comité Científico de la Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) sobre condiciones de uso de determinadas sustancias distintas de vitaminas, minerales y plantas para ser empleadas en complementos alimenticios - 1. Revista del comité científico nº 17. 2012 Full text (in our servers)
  11. Brown LD, Cheung A, Harwood JE, Battaglia FC. Inositol and mannose utilization rates in term and late-preterm infants exceed nutritional intakes. J Nutr. 2009 Abstract Full text (link to original source)
  12. Huisman M, van Beusekom CM, Lanting CI, Nijeboer HJ, Muskiet FA, Boersma ER. Triglycerides, fatty acids, sterols, mono- and disaccharides and sugar alcohols in human milk and current types of infant formula milk. Eur J Clin Nutr. 1996 Abstract
  13. Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M. Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med. 1992 Abstract
  14. Pereira GR, Baker L, Egler J, Corcoran L, Chiavacci R. Serum myoinositol concentrations in premature infants fed human milk, formula for infants, and parenteral nutrition. Am J Clin Nutr. 1990 Abstract Full text (link to original source)
  15. Jenness R. The composition of human milk. Semin Perinatol. 1979 Abstract

Total visits

21,343

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM